INCB-086550

N/A

Report date: 2024/04/24 20:00:35
NME

Base Information

Drug NameINCB-086550
Drug Alias NameINCB-086550INCB-86550
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUkraineTaiwan +[7] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesIncyte Biosciences Japan Gk
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[6] 

Other Information

ATC CodeN/A
Related LinksN/A